Pathology & Laboratory Medicine News
-
A Shared Vision: Philanthropic Partnership Fuels Cancer Discoveries
MCW Cancer Center scientists and the WBCS are making a difference with the help of generous donors.
-
When Prostate Cancer Returns
MCW physician-scientists test new treatment for advanced prostate cancer.
-
Two Years Later, MCW Reflects on COVID-19: Dr. Nathan Ledeboer
Nathan Ledeboer, PhD, medical director and professor, praises teamwork and diversity amidst the last 2 years of the COVID-19 pandemic.
-
Dr. Kathleen Schmainda Receives Perfect Score on NCI MPI R01 to Establish a Consensus DSC-MRI Protocol
This five-year, $3.5 million grant will be done in collaboration with researchers from Brown University, Barrow Neurological Institute, and Mayo Clinic.
-
New Mouse Model Unlocks Drug Testing of Hormone-sensitive Human Breast Cancer
Mice engineered to produce human prolactin support growth and distant spread of estrogen receptor-positive breast tumors from patients.
-
Dr. Kathleen Schmainda Receives Grant to Use AI and Advanced MRI Methods to Identify Brain Tumors
Dr. Kathleen Schmainda was awarded a five-year, $2.7 million new R01 grant from the National Cancer Institute.
-
Leading the Way in Local Testing
MCW's successful diagnostic testing process for COVID-19 resulted from longstanding partnerships and relationships.
-
MCW Tissue Bank Receives College of American Pathologists Biorepository Accreditation
The MCW Tissue Bank received a three-year accreditation by the College of American Pathologists (CAP) in recognition of quality practices, efficient operations, and strong processing statistics. Congratulations to the program team on this milestone achievement!
-
Kenneth Iczkowski MD elected president-elect of the International Society of Urologic Pathology
The International Society of Urological Pathology issues guidelines for the practice of uropathology and provides educational opportunities for pathologists around the world.
-
MCW research team contributes to positive clinical trial results for myotubular myopathy gene therapy
Audentes Therapeutics, Inc., recently presented new positive data on ASPIRO, a Phase 1/2 clinical trial of AT132 for the treatment of X-linked Myotubular Myopathy. Early nonclinical translational studies and the pathological evaluation of muscle biopsies from ASPIRO have been performed in the laboratory of Michael W. Lawlor, MD, PhD.
Contact Us
Medical College of Wisconsin
Froedtert/Medical College Lab Building
FMCLB 226
9200 W. Wisconsin Ave.
Milwaukee, WI 53226-3522
(414) 805-6980 (fax)
